Skip to main content
. 2009 Dec 10;115(7):1425–1432. doi: 10.1182/blood-2009-09-242859

Table 1.

Inhibition of ITD-mutant (FLT3/ITD) and wild-type (WT) FLT3 autophosphorylation

Drug WT FLT3 IC50, medium, nM FLT3/ITD IC50, medium, nM FLT3/ITD IC50, plasma, nM In vivo t1/2, h
Lestaurtinib 10 2 700 825
Midostaurin 30 3 1700 24+26
Sorafenib 28 3 484 24+27
Sunitinib 2 1 ND 24+28
KW-2449 36 10 144 411
AC220 5 1 18 24+5

SEMK2 cells (wild-type FLT3) and Molm-14 cells (FLT3/ITD) were incubated with increasing concentrations of inhibitor. R values for all experiments were greater than 0.98. Sunitinib was not analyzed in plasma, as there are no active FLT3 AML trials with this agent. The plasma half-lives (In vivo t1/2) were obtained from early-phase clinical trial data (see references). ND indicates not determined.

HHS Vulnerability Disclosure